ETFs Seelos Therapeutics, Inc.

SEELQ

US81577F4063

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 12:25:32 2026-06-01 EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		0.00%	-

12-28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company